To study the effect of relocation from 3200m (Aksay) to 760m (Bishkek) in highlanderswith High Altitude Pulmonary Hypertension (HAPH) who permanently live >2500m on sleepdisordered breathing
This research in highlanders with HAPH diagnosed by echocardiography and defined by a
RV/RA >30 mmHg who permanently live at HA >2500 m will have nocturnal respiratory sleep
studies near their living altitude in Aksay at 3200 m and on night 1 and 6 at 760m after
relocation.
Other: SDB assessment
SDB will be assessed by respiratory polygraphy according to clinical standards
Inclusion Criteria:
- Permanently living >2500 m
- HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an
altitude of 3200 m
- Written informed consent
Exclusion Criteria:
- Highlanders who cannot follow the study investigations,
- Patients with moderate to severe concomitant lung disease (FEV1<70% or forced vital
capacity <70%), severe parenchymal lung disease, heavy smoking >20 cigarettes/day or
>20 pack-years.
- Coexistent unstable systemic hypertension or coronary artery disease that required
adjustment of medication within the last 2 months
- Regular use of medication that affects control of breathing (benzodiazepines,
opioids, acetazolamide)
Aksay Medical Center
Aksay Plateau, Naryn, Kyrgyzstan, Kyrgyzstan